

TABLE OF CONTENTS

April 16, 2007

No. 2037

BUSINESS

- 1 Daiichi Sankyo Sets Out To Become a “Global Pharma Innovator”
- To Hire Contract MRs in Selected Fields
- Panalidine to Be Transferred sanofi-aventis
- 2 Mochida to Increase MRs to 750 by FY2009
- 3 Industry’s Highest Growth Rate Recorded Twice in 2 Years: NBI
- Application for Neoangiogenesis Inhibitor Expected in 2010
- 4 Janssen’s Sales Drop 11.8% Due to NHI Price Cuts
- 4 **BUSINESS NEWS IN BRIEF**
- Santen Applies for DE-085 in Europe
- Sanofi-aventis Licenses TroVax from Oxford BioMedica
- BML Sells Off Dispensing Pharmacy Business
- JCROA Starts Introductory Monitor Training Program
- Global Sales of Ethical Drugs Up 7% to US\$643.0 Bil.: IMS Health
- 5 **ON THE MOVE**
- Hideyuki Ashikaga Appointed President of BD Japan
- 6 **Commentary**
- India Attracts Increasing Attention of Japanese Pharmas

REGULATORY

- 7 Abnormal Behaviors Reported from 128 Patients after Taking Tamiflu: *Koroshō*
- Researcher with Conflict of Interest Excluded from Study Team
- WG Created to Collect More Data
- Concern Expressed by Lawmaker about Tamiflu Stockpiling
- 8 Chugai’s Grants Go to 3 Institutions Whose Researchers Participate in Tamiflu Survey
- Considerations Were Made Not to Impair Impartiality When Making Donations: Chugai
- Sufficient Research Fund Should Be Provided: Health Minister
- 9 Permax Withdrawn from US Market
- 9 Data Protection Period Extended to 8 Years
- 10 Great Precautions Needed in Revising PMDA’s Employment Rule: Health Minister
- 10 Need for Relaxing PMDA’s Employment Regulations Pointed Out
- 10 **REGULATORY NEWS IN BRIEF**
- Novartis Suspends Marketing, Sales of Zelnorm in the US
- Enzastaurin Designated as Orphan Drug in EU: Eli Lilly
- PMDA to Upgrade its Info. Systems in Earnest
- 11 **TOPICS**
- Wyeth Salutes WHO Call to Action to Combat Pneumococcal Disease

R&D

- 12 EFPIA, EC Embark on Joint Drug Discovery Research Project
- Dialogue Essential for Innovation: Vice-President Mr Dehecq

- 13 Study Group on Early Approval of Safe, Effective Drugs
- 13/49 Companies Plan Multinational Clinical Trials within Next 3 Years for the First Time
- Joint Consultation by FDA, EMEA Not Functioning Well: Mr Kawaoto
- 14 Ordinary Single-Dose Tox Studies Sufficient to Initiate MD Studies: Symposium
- 14 **R&D NEWS IN BRIEF**
- AstraZeneca to Conduct 20 PI Trials in Japan in 2007
- Baxter Announces Final PI/II Data for H5N1 Influenza Vaccine
- Positive Interim PII Data for VEGF Trap-Eye Reported: Bayer HealthCare, Regeneron
- Japan Should Begin by Taking Part in Small-Scale Asian Studies: Mr Uechi
- GL on Licensing of Patented Research Tools Issued
- 15 **TOPICS**
- Abilify Receives PSJ Award: Otsuka

COMMENTARY

- 17 **Maurer’s Healthcare Insight (85)**
- Updating the Numbers: P. Reed Maurer

MEDICAL DEVICES

- 18 Use of 9 Reagents for Pancreatic Islet Transplantations Restricted
- 18 **MEDICAL DEVICE NEWS IN BRIEF**
- ARKRAY Launches a Series of New Products
- GEYMS Launches Voluson E8
- IMJ Takes Over POCT Products from Nihon Schering
- Lab Test Market in 2006 to Grow by 3.2% to ¥389.4 billion
- METIS Consortium Calls for Relaxation of GCP

GENERICS

- 20 26 Complaints Received Regarding Supply of Generics in 1 Year
- *Koroshō* Calls For Further Efforts to Improve Quality of Generics
- 20 PSJ Luncheon Seminar
- Drug Companies Should Provide Info. Commensurate with NHI Prices: Prof. Sakaeda
- Pharmacists Should Play Important Role in Selection of Drugs: Dr Masada
- 21 **Survey**
- 90% of Doctors Predict Increases in Cerebro-, Cardiovascular Diseases: Prof. Teramoto
- Lack of Symptoms Reduces Consultation Rate for NTG: Pfizer Survey

SELF-MEDICATION

- 23 Daiichi Sankyo Healthcare to Focus on Switch OTC Drugs
- 23 **TOPICS**
- ACNielsen, So-net M3 to Start Radar Track Service